Potential conflict of interest to note: Several of the study authors worked for the company who produced the product used in the study
First, phase II clinical trials evaluating MOTS-c in type 2 diabetes and sarcopenia are in development, and their results will provide the first randomized controlled evidence in humans to define therapeutic doses with statistical rigor
Speeding up tissue repair and recovery When youre dealing with an injury, you want to get back on your feet as quickly as possible
Pegaptanib, a VEGF antagonist with a three-dimensionally structured aptamer, was initially used to inhibit pathological neovascularization and reverse disease progression but was later removed from the market
For others, especially those needing nerve or anemia support, improvements might take weeks or months with consistent injections
The ascorbateglutathione pathway: new subcellular horizons The early work on redox exchange between ascorbate and glutathione had investigated extracts of whole tissues